|Kura Oncology -- USA Stock|| |
USD 17.45 0.45 2.51%
Co-Founder, Chief Scientific Officer
Dr. Yi Liu, Ph.D. is Chief Scientific Officer of Kura Oncology, Inc. Since March 2015. Dr. Liu cofounded Prior Kura in August 2014 and served as the Chief Scientific Officer of Prior Kura from October 2014 until the Upstream Merger in March 2015. Prior to that, Dr. Liu cofounded and served as Chief Scientific Officer of Wellspring Biosciences LLC, a private biopharmaceutical company, from July 2012 to September 2014. Dr. Liu also cofounded Intellikine, Inc., a private biopharmaceutical company, where he served as Vice President of Drug Discovery from 2007 to May 2012, until its acquisition by Takeda Pharmaceutical Company Limited. Prior to Intellikine, Dr. Liu was the head of the drug design group at the Genomics Institute of the Novartis Research Foundation. Earlier in his career, he held senior scientist positions at both SGX Pharmaceuticals, Inc., a public biopharmaceutical company which was acquired by Eli Lilly and Company in 2008, and Curagen Corporationrationration, a public biopharmaceutical development company
Age: 46 Founder Since 2015
Liu received his Ph.D. in Biochemistry from Princeton University, his MSc in computational chemistry from Beijing University and his BE in Chemical Engineering from Tsinghua University.
The company has return on total asset (ROA)
of (27.22) %
which means that it has lost $27.22 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (51.83) %
meaning that it created substantial loss on money invested by shareholders.
The company currently holds 7.1 M in liabilities with Debt to Equity (D/E) ratio of 8.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Kura Oncology has Current Ratio of 9.25 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. The company was founded in 2014 and is headquartered in San Diego, California. Kura Oncology operates under Biotechnology classification in USA and traded on NASDAQ. It employs 31 people.Kura Oncology (KURA) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 31 people. Kura Oncology is listed under Pharmaceutical Products category by Fama And French industry classification.
Kura Oncology Leadership Team
|Troy Wilson, Chairman|
|Steven Stein, Director|
|Faheem Hasnain, Director|
|Annette North, President|
|Liu Yi, Founder|
|Thomas Malley, Director|
|Pingda Ren, SVP, Ph.D|
|Antonio Gualberto, Executive, Ph.D|
|Heidi Henson, CFO|
|Robert Hoffman, Director, CPA|
Stock Performance Indicators
Most of Macroaxis users are now bullish on Kura Oncology. What is your trading attitude regarding investing in Kura Oncology? Are you bullish or bearish?
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations